ASCO 2023
ASCO 2023
American Society of Clinical Oncology 2023 Annual Meeting
Advertisement
Emily MenendezASCO 2023 | June 3, 2023
The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress.
Read More
Emily MenendezASCO 2023 | June 3, 2023
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Zachary BessetteASCO 2023 | June 2, 2023
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
Zachary BessetteASCO 2023 | June 2, 2023
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
Emily MenendezASCO 2023 | June 1, 2023
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
Emily MenendezASCO 2023 | June 1, 2023
Results of the STARTAR phase 2 trial on salvage RT plus apalutamide and docetaxel were presented at the 2023 ASCO meeting.
Emily MenendezASCO 2023 | June 1, 2023
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
Emily MenendezASCO 2023 | June 1, 2023
A post-hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Emily MenendezASCO 2023 | May 31, 2023
Questions from the surveys were rated as relevant or nonrelevant by patients with RCC.
Emily MenendezASCO 2023 | May 31, 2023
Results outlined patient-reported outcomes from the TALAPRO-2 trial on first-line talazoparib plus enzalutamide for mCRPC.
Emily MenendezASCO 2023 | May 31, 2023
A study from ASCO 2023 surveyed patients to determine how they prioritize their treatment selection for mRCC.
Emily MenendezASCO 2023 | May 31, 2023
Researchers conducted an exploratory follow-up analysis of HRQoL in treament with nivolumab plus cabozantinib vs sunitinib.
Zachary BessetteASCO 2023 | May 30, 2023
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
Zachary BessetteASCO 2023 | May 30, 2023
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
Zachary BessetteASCO 2023 | May 30, 2023
The prevalence, outcomes of patients with HRR mutations who initiated 1L mCRPC treatment with a novel hormonal therapy.
Zachary BessetteASCO 2023 | May 26, 2023
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...
Zachary BessetteASCO 2023 | May 26, 2023
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
Zachary BessetteASCO 2023 | May 26, 2023
The largest analysis of outcomes for patients with sarcomatoid or rhabdoid metastatic nccRCC treated with IO-based regimens.
Zachary BessetteASCO 2023 | May 26, 2023
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance.
Advertisement
Advertisement
Advertisement